Matches in Nanopublications for { <http://rdf.disgenet.org/resource/nanopub/NP383545.RAV_hL3kqGD2r9PSUiledF9FqVAP3Fk1qyejE19G4uyfw130_assertion> ?p ?o ?g. }
Showing items 1 to 6 of
6
with 100 items per page.
- NP383545.RAV_hL3kqGD2r9PSUiledF9FqVAP3Fk1qyejE19G4uyfw130_assertion type Assertion NP383545.RAV_hL3kqGD2r9PSUiledF9FqVAP3Fk1qyejE19G4uyfw130_head.
- NP383545.RAV_hL3kqGD2r9PSUiledF9FqVAP3Fk1qyejE19G4uyfw130_assertion description "[E2A-PBX1+ adult ALL should be considered for intensified treatment strategies and monitoring of minimal residual disease.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP383545.RAV_hL3kqGD2r9PSUiledF9FqVAP3Fk1qyejE19G4uyfw130_provenance.
- NP383545.RAV_hL3kqGD2r9PSUiledF9FqVAP3Fk1qyejE19G4uyfw130_assertion evidence source_evidence_literature NP383545.RAV_hL3kqGD2r9PSUiledF9FqVAP3Fk1qyejE19G4uyfw130_provenance.
- NP383545.RAV_hL3kqGD2r9PSUiledF9FqVAP3Fk1qyejE19G4uyfw130_assertion SIO_000772 12580965 NP383545.RAV_hL3kqGD2r9PSUiledF9FqVAP3Fk1qyejE19G4uyfw130_provenance.
- NP383545.RAV_hL3kqGD2r9PSUiledF9FqVAP3Fk1qyejE19G4uyfw130_assertion wasDerivedFrom befree-2016 NP383545.RAV_hL3kqGD2r9PSUiledF9FqVAP3Fk1qyejE19G4uyfw130_provenance.
- NP383545.RAV_hL3kqGD2r9PSUiledF9FqVAP3Fk1qyejE19G4uyfw130_assertion wasGeneratedBy ECO_0000203 NP383545.RAV_hL3kqGD2r9PSUiledF9FqVAP3Fk1qyejE19G4uyfw130_provenance.